Idorsia Reports Aprocitentan Blood Pressure Reductions in Obesity and CKM Analyses

At AHA 2026, Phase 3 PRECISION analyses showed rapid double-digit blood pressure reductions among patients with obesity and CKM, improved UACR by about 50% in CKM patients, and stable renal function.